HC Wainwright Reaffirms Buy Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

HC Wainwright reaffirmed their buy rating on shares of Karyopharm Therapeutics (NASDAQ:KPTI) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $7.00 price target on the stock.

KPTI has been the subject of a number of other research reports. Royal Bank of Canada reiterated an “outperform” rating and issued a $3.00 price target on shares of Karyopharm Therapeutics in a research note on Monday, February 10th. Piper Sandler raised their target price on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, StockNews.com downgraded Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $5.00.

Karyopharm Therapeutics Stock Performance

Shares of NASDAQ:KPTI opened at $0.61 on Thursday. Karyopharm Therapeutics has a 12 month low of $0.53 and a 12 month high of $1.70. The company’s fifty day simple moving average is $0.66 and its 200 day simple moving average is $0.76.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02. The business had revenue of $30.54 million during the quarter, compared to analyst estimates of $30.29 million. Sell-side analysts expect that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

Large investors have recently bought and sold shares of the company. GSA Capital Partners LLP boosted its position in shares of Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock worth $1,474,000 after acquiring an additional 792,283 shares in the last quarter. FMR LLC boosted its holdings in shares of Karyopharm Therapeutics by 26.1% in the 3rd quarter. FMR LLC now owns 369,723 shares of the company’s stock valued at $307,000 after purchasing an additional 76,510 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Karyopharm Therapeutics by 3.3% in the 3rd quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company’s stock valued at $1,125,000 after purchasing an additional 43,856 shares in the last quarter. Marshall Wace LLP boosted its holdings in shares of Karyopharm Therapeutics by 15.3% in the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after purchasing an additional 319,187 shares in the last quarter. Finally, TD Waterhouse Canada Inc. acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at $32,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).